Cathepsin D and Breast Cancer

European Journal of Cancer

Volumn 32, Issue 1, 1996, Pages 15-24

  Westley, B R ^a   May, F E B ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D;

BREAST CANCER; FEMALE; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

BREAST NEOPLASMS; CATHEPSIN D; CELL DIVISION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGENS; FEMALE; GENES, REGULATOR; HUMANS; IMMUNORADIOMETRIC ASSAY; NEOPLASM METASTASIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0029966513     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00530-7     Document Type: Article

References (78)

1. Matus A, Green GDJ. Age-related increase in a cathepsin D like protease that degrades brain microtubule-associated proteins. Biochemistry 1987, 26, 8083-8086.
2. Woessner JF. In Barrett AJ, Dingle JT. Tissue Proteinases. New York, North Holland, 1971, 669-676.
3. Van Nort JM, Van Der Drift ACM. The selectivity of cathepsin D suggests an involvement of the enzyme in the generation of T-cell epitopes. J Biol Chem 1989, 264, 14159-14164.
4. Westley B, Rochefort H. Estradiol induced proteins in the MCF-7 human breast cancer cell line. Biochem Biophys Res Commun 1979, 90, 410-416.
5. Westley B, Rochefort H. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 1980, 20, 353-362.
6. Morisset M, Capony F, Rochefort H. The 52-kDa estrogen-induced protein secreted by MCF-7 cells is a lysosomal acidic protease. Biochem Biophys Res Commun 1986, 138, 102-109.
7. Capony F, Garcia M, Capdevielle J, Rougeot C, Ferrara P, Rochefort H. Purification and first characterization of the secreted and cellular 52-kDa proteins regulated by estrogens in human-breast cancer cells. Eur J Biochem 1986, 161, 505-512.
8. Westley BR, May FEB. Oestrogen regulates cathepsin D mRNA levels in oestrogen responsive human breast cancer cells. Nucleic Acids Res 1987, 15, 3773-3786.
9. Augereau P, Garcia M, Mattei MG, et al. Cloning and sequencing of the 52K cathepsin D complementary deoxyribonucleic acid of MCF-7 breast cancer cells and mapping on chromosome 11. Mol Endocrinol 1988, 2, 186-192.
10. Vignon F, Capony F, Chambon M, et al. Autocrine growth stimulation of the MCF-7 breast cancer cells by the estrogen-regulated 52K protein. Endocrinology 1986, 118, 1537-1545.
11. Garcia M, Derocq D, Pujol P, Rochefort H. Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 1990, 5, 1809-1814.
12. Liaudet E, Garcia M, Rochefort H. Cathepsin D maturation and its stimulatory effect on metastasis are prevented by addition of KDEL retention signal. Oncogene 1994, 9, 1145-1154.
13. Karey KP, Sirbasku DA. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and estradiol. Cancer Res 1988, 48, 4083-4092.
14. Stewart AJ, Westley BR, May FEB. Modulation of the proliferative response of breast cancer cells to growth factors by oestrgen. Br J Cancer 1992, 66, 640-648.
15. Stewart AJ, Piggott NH, May FEB, Westley BR. Mitogenic activity of procathepsin D purified from conditioned medium of breast-cancer cells by affinity chromatography on pepstatinylagarose. Int J Cancer 1994, 57, 715-718.
16. Vetvicka V, Vektvickova J, Fusek M. Effect of human procathepsin D on proliferation of human cell lines. Cancer Lett 1994, 79, 131-135.
17. Mathieu M, Rochefort H, Barenton B, Prebois C, Vignon F. Interations of cathepsin D and insulin-like growth factor-II (IGF-II) on the IGF-II/mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II. Mol Endocrinol 1990, 4, 1327-1335.
18. Fusek M, Vetvicka V. Mitogenic function of human procathepsin D: the role of the propeptide. Biochem J 1994, 303, 775-780.
19. Mathieu M, Vignon F, Capony F, Rochefort H. Estradiol down-regulates the mannose-6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: a receptor saturation mechanism to increase the secretion of lysosomal proenzymes. Mol Endocrinol 1991, 5, 815-822.
20. Conover CA, De Leon DD. Acid-activated insulin-like growth factor-binding protein-3 proteolysis in normal and transformed cells: role of cathepsin D. J Biol Chem 1994, 269, 7076-7080.
21. Briozzo P, Badet J, Capony F, et al. MCF-7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D. Exp Cell Res 1991, 194, 252-259.
22. Mareel MM, De Baestselier P, Van Roy FM (eds). Mechanisms of Invasion and Metastasis. Boston, Massachusetts, CRC Press, 1991.
23. r 52,000 cathepsin D secreted by breast cancer cells. Cancer Res 1988, 48, 3688-3692.
24. Montcourrier P, Mangeat PH, Salazar G, et al. Cathepsin D in breast cancer cells can digest extracellular matrix in large acidic vesicles. Cancer Res 1990, 50, 6045-6054.
25. Johnson MD, Torri JA, Lippman ME, Dickson RB. The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res 1993, 53, 873-877.
26. Johnson MD, Westley BR, May FEB. Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells. Br J Cancer 1989, 48, 5183-5187.
27. Maudelonde T, Escot C, Pujol P, et al. In vivo stimulation by tamoxifen of cathepsin D RNA levels in breast cancer. Eur J Cancer 1994, 30A, 2049-2053.
28. Faust PL, Kornfield S, Chirgwin JM. Cloning and sequence analysis of cDNA for human cathepsin D. Proc Natl Acad Sci USA 1985, 82, 4910-4914.
29. Conner GE, Udey JA, Pinto C, Sola J. Nonhuman cells correctly sort and process the human lysosomal enzyme cathepsin D. Biochemistry 1989, 28, 3530-3533.
30. Birch NP, Loh YP. Cloning, sequence and expression of rat cathepsin D. Nucleic Acids Res 1990, 18, 6445-6446.
31. Grusby MJ, Mitchell S, Glimcher L. Molecular cloning of mouse cathepsin D. Nucleic Acids Res 1990, 18, 4008.
32. Diedrich JF, Staskus KA, Retzel EF, Haase AT. Nucleotide sequence of a cDNA encoding mouse cathepsin D. Nucleic Acids Res 1990, 18, 7184.
33. May FEB, Smith DJ, Westley BR. The human cathepsin D encoding gene is transcribed from an estrogen-regulated and a constitutive start point. Gene 1993, 134, 277-282.
34. Cavaillès V, Augereau P, Rochefort H. Cathepsin D gene is controlled by a mixed promoter, and estrogens stimulate only TATA-dependent transcription in breast cancer cells. Proc Natl Acad Sci USA 1993, 90, 203-207.
35. Redecker B, Heckendorf B, Grosch H-W, Mersmann G, Hasilik A. Molecular organisation of the human cathepsin D gene. DNA and Cell Biol 1991, 10, 423-431.
36. Augereau P, Miralles F, Cavaillès V, Gaudelet C, Parker M, Rochefort H. Characterization of the proximal estrogen-responsive element of human cathepsin D gene. Mol Endocrinol 1994, 8, 693-703.
37. Wu-Peng XS, Pugliese TE, Dickerman HW, Pentecost BT. Delineation of sites mediating estrogen regulation of the rat creatine kinase-B gene. Mol Endocrinol 1992, 6, 231-240.
38. Kastner P, Krust A, Turcotte B, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBOJ 1990, 9, 1603-1614.
39. Cavaillès V, Augereau P and Rochefort H. Cathepsin D gene of human MCF-7 cells contains estrogen-responsive sequences in its 5′ proximal flanking region. Biochem Biophys Res Commun 1991, 174, 816-824.
40. Krishnan V, Wang X, Safe S. Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J Biol Chem 1994, 269, 15 912-15917.
41. Reid WA, Valler MJ, Kay J. Immunolocalisation of cathepsin D in normal and neoplastic tissues. J Clin Path 1986, 39, 1323-1330.
42. Tandon AK, Clark G, Chamness GC, Chirgwin JM, McGuire WL. Cathepsin D and prognosis in breast cancer. N Engl J Med 1990, 322, 297-302.
43. Eng Tan P, Benz CC, Dollbaum C, et al. Prognostic value of cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay. Ann Oncol 1994, 5, 329-336.
44. r 52,000 glycoprotein: characterisation and immunodetection in MCF-7 cells. Cancer Res 1985, 45, 709-716.
45. r 52,000 precursor of cathepsin D in human breast cancer cells. Cancer Res 1988, 48, 3709-3715.
46. Freiss G, Vignon F, Pau B, Paolucci F, Rochefort H. A two-site immunoenzymometric assay of 52-kDa pro-cathepsin D and its use in human breast diseases. Clin Chem 1989, 35, 234-237.
47. Rogier H, Freiss G, Besse M-G, et al. Two-site immunoenzymometric assay for the 52-kDa cathepsin D in cytosols of breast cancer tissues. Clin Chem 1989, 35, 81-85.
48. Benraad TJ, Geurts-Moespot A, Sala M, et al. Quality control of cathepsin-D measurement by EORTC receptor study group. Eur J Cancer 1992, 28, 71-75.
49. Early Breast Cancer Triallists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992, 339, 1-15.
50. Early Breast Cancer Triallists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992, 339, 71-85.
51. Garcia M, Lacombe MJ, Duplay H, et al. Immunohistochemical distribution of the 52-kDa protein in mammary tumours: a marker associated with cell proliferation rather than with hormone responsiveness. J Steroid Biochem 1987, 27, 439-445.
52. r 52,000 cathepsin D in 182 breast cancer cytosols: low correlation with other prognostic parameters. Cancer Res 1988, 48, 462-466.
53. Thorpe SM, Rochefort H, Garcia M, et al. Association between high concentration of M, 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 1989, 49, 6008-6014.
54. Spyratos F, Brouillet JP, Defrenne A, et al. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet 1989, ii, 1115-1118.
55. Romain S, Muracciole X, Varette I, et al. Le cathepsine-D: un facteur pronostique indépendant dans le cancer du sein. Bull Cancer 1990, 77, 439-447.
56. Duffy MJ, Brouillet JP, Reilly D, et al. Cathepsin D concentration in breast cancer cytosols: correlation with biochemical, histological, and clinical findings. Clin Chem 1991, 37, 101-104.
57. Namer M, Ramaioli A, Fontana X, et al. Prognostic value of total cathepsin D in breast tumors. Breast Cancer Res Treatment 1991, 19, 85-93.
58. Granata G, Coradini D, Cappelletti V, DiFronzo G. Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. Eur J Cancer 1991, 27, 970-972.
59. Kute TE, Shao ZM, Sugg NK, Long RT, Russell GB, Case LD. Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 1992, 52, 5198-5203.
60. Spyratos F, Martin PM, Hacène K, et al. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 1992, 84, 1266-1272.
61. Pujol P, Maudelonde T, Daures JP, et al. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 1993, 71, 2006-2012.
62. Foekens JA, Van Putten WLJ, Portengen H, et al. Prognostic value of ps2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol 1993, 11, 899-908.
63. Gion M, Mione R, Pappagallo GL, et al. PS2 in breast cancer-alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Br J Cancer 1993, 68, 374-379.
64. Seshadri R, Horsfall DJ, Firgaira F, et al. The relative prognostic significance of total cathepsin D and her-2/ner oncogene amplification in breast cancer. Int J Cancer 1994, 56, 61-65.
65. Stonelake PS, Baker PG, Gillespie WM, et al. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Eur J Cancer 1994, 30A, 5-11.
66. Ravdin PM. Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treatment 1993, 24, 219-226.
67. Ravdin PM, Tandon AK, Allred DC, et al. Cathepsin D by Western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 1994, 12, 467-474.
68. Henry JA, McCarthy AL, Angus B, et al. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. Cancer 1990, 65, 265-271.
69. Domagala W, Striker G, Szadowska A, Dukowicz A, Weber K, Osborn M. Cathepsin D in invasive ductual NOS breast carcinoma as defined by immunohistochemistry. Am J Pathol 1992, 141, 1003-1012.
70. Kandalaft PL, Chang KL, Ahn CW, Traweek ST, Mehta P, Battifora H. Prognostic significance of immunohistochemical analysis of cathepsin D in low-stage breast cancer. Cancer 1993, 71, 2756-2763.
71. Winstanley JHR, Leinster SJ, Cooke TG, Westley BR, Platt-Higgins AM, Rudland PS. Prognostic significance of cathepsin-D in patients with breast cancer. Br J Cancer 1993, 67, 767-772.
72. Isola J, Weitz S, Visakorpi T, et al. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol 1993, 11, 36-43.
73. Têtu B, Brisson J, Côté C, Brisson S, Potvin D, Roberge N. Prognostic significance of cathepsin D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer 1993, 55, 429-435.
74. Joensuu H, Toikkanen S, Isola J. Stromal cell cathepsin D expression and long term survival in breast cancer. Br J Cancer 1995, 71, 155-159.
75. O'Donoghue AEMA, Poller DN, Bell JA, et al. Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells. Breast Cancer Res Treatment 1995, 33, 137-145.
76. Maudelonde T, Brouillet JP, Roger P, Giraudier V, Pages A, Rochefort H. Immunostaining of cathepsin D in breast cancer: quantification by computerised image analysis and correlation with cytosolic assay. Eur J Cancer 1992, 28A, 1686-1691.
77. Roger P, Montcourrier P, Maudelonde T, et al. Cathepsin D immunostaining in paraffin embedded breast cancer cells and macrophages. Human Pathol 1994, 25, 863-871.
78. Baldwin ET, Bhat TN, Gulnick S, et al. Crystal structure of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design. Proc Natl Acad Sci USA 1993, 90, 6796-6800.